Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.57 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.57 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.57 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.57 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.57 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 2/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.57 |
| ▸ | TACR2 | P21452 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SHBG | P04278 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.57 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12114083 | 0.98 | ESR1 (0.59) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| Water SCHEMBL9717479 | 0.96 | ESR1 (0.57) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| Hydrochloric Acid SCHEMBL4981893 | 0.83 | HSP90AA1 (0.73) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL2511615 | 0.82 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL6681490 | 0.82 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL23849704 | 0.82 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL6684861 | 0.82 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL4037557 | 0.82 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL10571467 | 0.82 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL10758361 | 0.82 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675855-B1 | ISOQUINOLINES AND 1H-2-BENZOPYRANES FOR USE IN THE TREATMENT OF EPILEPSY | UNIV LEUVEN KATH (BE) | 2024-08-28 | — | — | EP | claimed |
| US-11826364-B2 | Treatment for epilepsy | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-28 | — | — | US | claimed |
| US-20230108004-A1 | TREATMENT OF EPILEPSY WITH PLINABULIN OR HALIMIDE OR DIKETOPIPERAZINE DERIVATIVES | UNIV LEUVEN KATH (BE) | 2023-04-06 | — | — | US | claimed |
| CN-115739124-A | Novel cadmium sulfide nanosphere photocatalyst and preparation method thereof | 电子科技大学长三角研究院(湖州) | 2023-03-07 | — | — | CN | claimed |
| CN-115722217-A | Novel tungsten oxide nanorod photocatalyst and preparation method thereof | 电子科技大学长三角研究院(湖州) | 2023-03-03 | — | — | CN | claimed |
| CN-115701972-A | Compositions comprising zinc and an antimicrobial agent | 联合利华知识产权控股有限公司 | 2023-02-14 | — | — | CN | claimed |
| CN-111093775-B | Method for controlling staining of teeth by cationic antimicrobial agents | 联合利华知识产权控股有限公司 | 2022-11-08 | — | — | CN | claimed |
| CN-114989044-A | Catalytic synthesis method of dicarbamate | 中国科学院过程工程研究所 | 2022-09-02 | — | — | CN | claimed |
| US-20220265638-A1 | TREATMENT FOR EPILEPSY | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2022-08-25 | — | — | US | claimed |
| CN-112515987-A | Oral care compositions with adducts of clay and antibacterial agent | 荷兰联合利华有限公司 | 2021-03-19 | — | — | CN | claimed |
| US-20050025833-A1 | Pharmaceutical composition and method for transdermal drug delivery | PERRIGO ISRAEL PHARMACEUTICALS LTD. (IL) | 2005-02-03 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20030091620-A1 | Transdermal drug delivery systems containing quaternary ammonium salts and methods of using the same | FIKSTAD DAVID (US) | 2003-05-15 | — | — | US | claimed |
| EP-1066280-A4 | HALIMIDE, A CYTOTOXIC MARINE NATURAL PRODUCT, AND DERIVATIVES THEREOF | UNIV CALIFORNIA (US) | 2003-02-26 | — | — | EP | claimed |
| EP-1217975-A1 | USING QUATERNARY AMMONIUM SALTS FOR TRANSDERMAL DRUG DELIVERY | Watson Pharmaceuticals, Inc. (US) | 2002-07-03 | — | — | EP | claimed |
| WO-2001017472-A1 | USING QUATERNARY AMMONIUM SALTS FOR TRANSDERMAL DRUG DELIVERY | WATSON PHARMACEUTICALS, INC. (US) | 2001-03-15 | — | — | WO | claimed |
| EP-1066280-A1 | HALIMIDE, A CYTOTOXIC MARINE NATURAL PRODUCT, AND DERIVATIVES THEREOF | The Regents of the University of California (US) | 2001-01-10 | — | — | EP | claimed |
| US-6069146-A | Halimide, a cytotoxic marine natural product, and derivatives thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-30 | — | — | US | claimed |
| WO-1999048889-A1 | HALIMIDE, A CYTOTOXIC MARINE NATURAL PRODUCT, AND DERIVATIVES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-09-30 | — | — | WO | claimed |
| US-3992432-A | Phase transfer catalysis of heterogeneous reactions by quaternary salts | CONTINENTAL OIL COMPANY (US) | 1976-11-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11826364-B2 | Treatment for epilepsy | GABARAPL2, HDAC2, GABRB2 | SLC6A2 1117/4885SLC6A3 2074/4885CHRM2 1135/4885 |
| US-20030091620-A1 | Transdermal drug delivery systems containing quaternary ammonium salts and methods of using the same | SLC38A7, SUCNR1, SLC7A1 | SLC6A2 46/4885SLC6A3 311/4885CHRM2 1566/4885 |
| US-20220265638-A1 | TREATMENT FOR EPILEPSY | GABARAPL2, GABRB2, CNR2 | SLC6A2 911/4885SLC6A3 1958/4885CHRM2 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.